Radioactive therapy shows promise for tough prostate cancer

NCT ID NCT03939689

Completed Disease control Sponsor: Progenics Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested whether adding a radioactive drug (I-131-1095) to standard enzalutamide therapy helps men with a specific type of advanced prostate cancer that had worsened on another treatment. The study enrolled 120 men with PSMA-positive metastatic castration-resistant prostate cancer. Some received the radioactive drug plus enzalutamide, while others got enzalutamide alone. Researchers compared PSA levels, tumor response, and side effects between the groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: I-131-1095 (radioactive drug) and enzalutamide
What this could lead to: If it works, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a phase 2 trial with only 120 participants, so results may not apply to everyone. The radioactive drug can cause side effects like low blood cell counts, and it's not yet proven to improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER OF THE PROSTATE CASTRATION-RESISTANT PROSTATE CANCER METASTATIC PROSTATE CANCER PROGRESSIVE MCRPC PROSTATIC NEOPLASM

Contacts and locations

Show contact details

Locations

Centre Hospitalier Del' Universite de Montreal

Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Quebec

Québec, Quebec, Canada
Centre Hospitalier Universitaire de Sherbrooke

Sherbrooke, Quebec, Canada
City of Hope

Duarte, California, 91010, United States
Hoag Family Cancer Institute

Newport Beach, California, 92663, United States
Jewish General Hospital

Montreal, Quebec, Canada
LifeSpan Cancer Institute

Providence, Rhode Island, 09206, United States
London Health Sciences Centre

Toronto, Ontario, Canada
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Medstar Georgetown University Hospital

Washington D.C., District of Columbia, 20007, United States
SUNY Upstate Medical University

Syracuse, New York, 13210, United States
The Ottawa Hospital

Ottawa, Ontario, K1H 8L6, Canada
The University of Chicago

Chicago, Illinois, 60637, United States
Tulane Medical School

New Orleans, Louisiana, 70112, United States
UCLA

Los Angeles, California, 90095-7370, United States
University Health Network - Princess Margaret Cancer Centre

Toronto, Ontario, Canada
University of Iowa

Iowa City, Iowa, 52242, United States
University of Maryland

Baltimore, Maryland, 21201, United States
University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
University of Virginia Cancer Center

Charlottesville, Virginia, 22908, United States
University of Washington - Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
VA Greater Los Angeles Healthcare System

Los Angeles, California, 90073, United States
VA Palo Alto Healthcare System

Palo Alto, California, 94303, United States
Virginia Mason Medical Center

Seattle, Washington, 98101, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.